Solventum Corporation $SOLV Shares Sold by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC decreased its holdings in Solventum Corporation (NYSE:SOLV) by 27.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 6,057 shares of the company’s stock after selling 2,345 shares during the period. Prime Capital Investment Advisors LLC’s holdings in Solventum were worth $459,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Chelsea Counsel Co. increased its holdings in shares of Solventum by 720.7% in the second quarter. Chelsea Counsel Co. now owns 10,595 shares of the company’s stock valued at $804,000 after purchasing an additional 9,304 shares during the last quarter. ST Germain D J Co. Inc. increased its stake in shares of Solventum by 84.6% in the 2nd quarter. ST Germain D J Co. Inc. now owns 825 shares of the company’s stock worth $63,000 after acquiring an additional 378 shares during the last quarter. CX Institutional increased its stake in shares of Solventum by 11.7% in the 2nd quarter. CX Institutional now owns 2,376 shares of the company’s stock worth $180,000 after acquiring an additional 249 shares during the last quarter. ORG Wealth Partners LLC acquired a new stake in shares of Solventum in the 2nd quarter worth $71,000. Finally, Public Employees Retirement System of Ohio increased its position in Solventum by 0.9% during the second quarter. Public Employees Retirement System of Ohio now owns 63,719 shares of the company’s stock worth $4,832,000 after purchasing an additional 583 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on SOLV shares. Wells Fargo & Company raised their price objective on shares of Solventum from $79.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Monday, September 15th. Zacks Research upgraded shares of Solventum from a “hold” rating to a “strong-buy” rating in a report on Monday, September 15th. UBS Group began coverage on shares of Solventum in a report on Wednesday, October 1st. They set a “neutral” rating and a $77.00 price target for the company. Piper Sandler reissued an “overweight” rating and set a $94.00 target price (up previously from $87.00) on shares of Solventum in a research note on Friday, August 8th. Finally, Jefferies Financial Group began coverage on Solventum in a research note on Thursday, September 11th. They set a “hold” rating and a $80.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $84.89.

Solventum Trading Down 1.8%

Shares of NYSE SOLV opened at $70.53 on Friday. Solventum Corporation has a twelve month low of $60.70 and a twelve month high of $85.92. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14. The stock has a fifty day simple moving average of $72.75 and a 200-day simple moving average of $72.11. The stock has a market capitalization of $12.23 billion, a PE ratio of 32.65, a PEG ratio of 2.92 and a beta of 0.50.

Solventum (NYSE:SOLV) last released its earnings results on Thursday, August 7th. The company reported $1.69 earnings per share for the quarter, beating the consensus estimate of $1.45 by $0.24. The company had revenue of $2.16 billion during the quarter, compared to the consensus estimate of $2.12 billion. Solventum had a return on equity of 29.93% and a net margin of 4.52%.Solventum’s revenue was up 3.8% compared to the same quarter last year. During the same period in the previous year, the company posted $1.56 EPS. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, equities analysts forecast that Solventum Corporation will post 6.58 earnings per share for the current year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.